Maxime Dely: CAR T Cell Therapy Starts With Collection
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Before CAR T, there is the collection.
CAR T cell therapy begins well before the genetic modification of T cells: it starts with eukapheresis, which collects the patient’s mononuclear cells, including the T lymphocytes that will be used to manufacture the cellular product.
This first step is critical: cell composition, viability and collection quality can influence the subsequent manufacturing process.
Apheresis technology is essential, but it is not enough. Successful collection also relies on the expertise, experience and vigilance of nurses, who adapt the procedure to each patient.
Before manufacturing CAR T cells, we first need to successfully collect them.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome